Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Quantification of amyloid PET for future clinical use: a state-of-the-art review
Hugh Pemberton, Lyduine E. Collij, Fiona Heeman, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 10, pp. 3508-3528
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
Marta Milà‐Alomà, Nicholas J. Ashton, Mahnaz Shekari, et al.
Nature Medicine (2022)
Open Access | Times Cited: 236
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 55
Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia
Laura Winchester, Eric L. Harshfield, Shi Liu, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 12, pp. 5860-5871
Open Access | Times Cited: 47
Gut microbiota-driven metabolic alterations reveal gut–brain communication in Alzheimer’s disease model mice
Yijing Chen, Yinhu Li, Yingying Fan, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 21
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 9
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable
Gill Farrar, Christopher J. Weber, Gil D. Rabinovici
The Journal of Prevention of Alzheimer s Disease (2025) Vol. 12, Iss. 1, pp. 100008-100008
Open Access | Times Cited: 2
Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease
Sarah M. Hartz, Suzanne E. Schindler, Marissa Streitz, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Jangampalli Adi Pradeepkiran, Javaria Baig, Md Ariful Islam, et al.
Aging and Disease (2024)
Open Access | Times Cited: 14
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Antoine Leuzy, Lars Lau Rakêt, Victor L. Villemagne, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 5833-5848
Open Access | Times Cited: 13
Unveiling New Strategies Facilitating the Implementation of Artificial Intelligence in Neuroimaging for the Early Detection of Alzheimer’s Disease
Maudlyn O. Etekochay, Amoolya Rao Amaravadhi, Gabriel Villarrubia González, et al.
Journal of Alzheimer s Disease (2024) Vol. 99, Iss. 1, pp. 1-20
Closed Access | Times Cited: 11
Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology
Mahnaz Shekari, David Vállez García, Lyduine E. Collij, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5102-5113
Open Access | Times Cited: 9
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study
Ariane Bollack, Lyduine E. Collij, David Vállez García, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3429-3441
Open Access | Times Cited: 8
Cognivue Clarity® characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study
James E. Galvin, Michael J. Kleiman, Paul W. Estes, et al.
Journal of Alzheimer s Disease (2025)
Closed Access | Times Cited: 1
Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods
Aleksandar Jovalekic, Núria Roé-Vellvé, Norman Koglin, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 11, pp. 3276-3289
Open Access | Times Cited: 19
Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification
Ariane Bollack, Hugh Pemberton, Lyduine E. Collij, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 5232-5252
Open Access | Times Cited: 18
The Future of (Radio)‐Labeled Compounds in Research and Development within the Life Science Industry
Volker Derdau, Charles S. Elmore, Thomas Härtung, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 52
Open Access | Times Cited: 17
Quantitative Brain Amyloid PET
William J. Jagust, Venkata S. Mattay, Daniel M. Krainak, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 5, pp. 670-678
Open Access | Times Cited: 7
Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline
Débora Elisa Peretti, Cecilia Boccalini, Federica Ribaldi, et al.
Brain (2024) Vol. 147, Iss. 12, pp. 4094-4104
Open Access | Times Cited: 7
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Lyduine E. Collij, Ariane Bollack, Renaud La Joie, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 7
A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F]flortaucipir PET in a memory clinic cohort
Gregory Mathoux, Cecilia Boccalini, Débora Elisa Peretti, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 51, Iss. 6, pp. 1639-1650
Open Access | Times Cited: 6
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Rumiana Tenchov, Janet M. Sasso, Qiongqiong Angela Zhou
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 21, pp. 3800-3827
Open Access | Times Cited: 6
Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
Mahnaz Shekari, Eline E. Verwer, Maqsood Yaqub, et al.
EJNMMI Physics (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 15
Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation
Emily Johns, Hillary Vossler, Christina B. Young, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5299-5310
Open Access | Times Cited: 5
SV2A PET imaging in human neurodegenerative diseases
Mahsa Shanaki Bavarsad, Lea T. Grinberg
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top